Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
News|Articles|July 10, 2025
Experts Highlight Consequences of Medicaid Rollbacks Due to Budget Bill
Author(s)Julia Bonavitacola
Fact checked by: Christina Mattina
A webinar held by KFF on July 9 emphasized the immediate effects of the new budget bill, highlighting the impacts on Medicaid and health spending in the next decade.
Advertisement
Advertisement
When the House passed the budget bill dubbed the One Big Beautiful Bill Act on July 3, 2025,1 health officials warned of the long-lasting effects that the move could have, including individuals losing health care coverage and the loss of funding for hospitals across the country.2 On July 9, KFF hosted a webinar to discuss some of these effects and explain how they would be addressed in the future.
Related to this article
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
Expert panel discussions covered AI and community access, chronic lymphocytic leukemia, myeloma, and breast and lung cancers.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply
Advertisement
Advertisement